Evidence map›Paper›PMID 42120627›Full record

ReviewAAPS PharmSciTech2026

Palatability-by-Design for Oral Drug Products: A Unified Framework for Evaluation and Optimization.

Qiaorui Li, Junzhe Xi, Zhenda Liu, Yingying Mu, Lijie Zhao, Lan Shen

Abstract readReview
PubMed Publisher
In one paragraph

Review in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Qiaorui LiEngineering Research Center of Modern Preparation Technology of Traditional Chinese Medicine of Ministry of Education, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China.ORCID http://orcid.org/0009-0004-9388-2053
Junzhe XiSchool of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China.ORCID http://orcid.org/0009-0006-3556-4916
Zhenda LiuEngineering Research Center of Modern Preparation Technology of Traditional Chinese Medicine of Ministry of Education, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China.ORCID http://orcid.org/0009-0008-9486-8287
Yingying MuEngineering Research Center of Modern Preparation Technology of Traditional Chinese Medicine of Ministry of Education, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China.ORCID http://orcid.org/0009-0003-6233-6634
Lijie ZhaoEngineering Research Center of Modern Preparation Technology of Traditional Chinese Medicine of Ministry of Education, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China. 0000002383@shutcm.edu.cn.ORCID http://orcid.org/0000-0002-3328-9694
Lan ShenEngineering Research Center of Modern Preparation Technology of Traditional Chinese Medicine of Ministry of Education, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China. alansusu@sina.com.ORCID http://orcid.org/0000-0001-6868-7986

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Palatability is a critical determinant of acceptability and adherence for oral drug products, especially in pediatric and geriatric populations, yet its evaluation remains fragmented across dosage forms and often disconnected from formulation-development decisions. In this review, we propose Palatability-by-Design (PbD) as a unified framework that treats palatability not as a loosely defined sensory outcome, but as a development variable with identifiable failure modes, measurable sensory critical quality attributes (CQAs), and controllable formulation/process levers. We first define a two-dimensional framework comprising swallowability (oral physical comfort) and palatability (sensory appreciation), and then outline major sensory failure modes that are relevant to oral drug development. Next, we compare subjective and objective evaluation methods using a fit-for-purpose logic, emphasizing decision relevance, surrogate calibration, and the need to anchor instrumental readouts to perception-relevant endpoints. We further integrate these elements into a PbD workflow that links sensory CQAs to risk assessment, formulation/process variables, acceptance criteria, and verification. Finally, we summarize failure-mode-guided optimization strategies, including taste masking and dosage-form modification, and discuss future needs for data standardization, translational calibration, and patient-centred implementation. By aligning sensory science with pharmaceutical quality and control logic, PbD provides a more practical basis for rational, patient-focused oral product development.

Indexed as

TasteAdministration, OralChemistry, PharmaceuticalDosage FormsDrug CompoundingDrug DesignDrug DevelopmentHumansPharmaceutical PreparationsDosage FormsPharmaceutical Preparationsoral dosage formpalatabilitypatient-centric designtaste evaluationtaste masking

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.